Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features.
Pérez-Carretero C, Hernández-Sánchez M, González T, Quijada-Álamo M, Martín-Izquierdo M, Santos-Mínguez S, Miguel-García C, Vidal MJ, García-De-Coca A, Galende J, Pardal E, Aguilar C, Vargas-Pabón M, Dávila J, Gascón-Y-Marín I, Hernández-Rivas JÁ, Benito R, Hernández-Rivas JM, Rodríguez-Vicente AE. Pérez-Carretero C, et al. Am J Hematol. 2022 Jul;97(7):903-914. doi: 10.1002/ajh.26578. Epub 2022 May 9. Am J Hematol. 2022. PMID: 35472012 Free article.
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
González-López TJ, Pascual C, Álvarez-Román MT, Fernández-Fuertes F, Sánchez-González B, Caparrós I, Jarque I, Mingot-Castellano ME, Hernández-Rivas JA, Martín-Salces M, Solán L, Beneit P, Jiménez R, Bernat S, Andrade MM, Cortés M, Cortti MJ, Pérez-Crespo S, Gómez-Núñez M, Olivera PE, Pérez-Rus G, Martínez-Robles V, Alonso R, Fernández-Rodríguez A, Arratibel MC, Perera M, Fernández-Miñano C, Fuertes-Palacio MA, Vázquez-Paganini JA, Gutierrez-Jomarrón I, Valcarce I, de Cabo E, Sainz A, Fisac R, Aguilar C, Paz Martínez-Badas M, Peñarrubia MJ, Calbacho M, de Cos C, González-Silva M, Coria E, Alonso A, Casaus A, Luaña A, Galán P, Fernández-Canal C, Garcia-Frade J, González-Porras JR. González-López TJ, et al. Am J Hematol. 2015 Mar;90(3):E40-3. doi: 10.1002/ajh.23900. Epub 2015 Jan 16. Am J Hematol. 2015. PMID: 25400215 Free article.
Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.
González-López TJ, Fernández-Fuertes F, Hernández-Rivas JA, Sánchez-González B, Martínez-Robles V, Alvarez-Román MT, Pérez-Rus G, Pascual C, Bernat S, Arrieta-Cerdán E, Aguilar C, Bárez A, Peñarrubia MJ, Olivera P, Fernández-Rodríguez A, de Cabo E, García-Frade LJ, González-Porras JR. González-López TJ, et al. Int J Hematol. 2017 Oct;106(4):508-516. doi: 10.1007/s12185-017-2275-4. Epub 2017 Jun 30. Int J Hematol. 2017. PMID: 28667351 Clinical Trial.
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
Osorio S, Escudero-Vilaplana V, Gómez-Centurión I, Pérez-López R, Ayala R, Vall-Llovera F, García-Gutierrez V, Gómez Casares MT, González San Miguel JD, Hernández-Rivas JÁ, Sánchez-Guijo F, Martínez-García AB, Villalón L, Conesa-García V, Rodriguez A, Casado F, Garcia-Gonzalez X, Sáez Perdomo MN, Baños Ú, Steegmann JL; CML Spanish Group (GELMC). Osorio S, et al. Ann Hematol. 2018 Nov;97(11):2089-2098. doi: 10.1007/s00277-018-3413-7. Epub 2018 Jun 28. Ann Hematol. 2018. PMID: 29955943 Clinical Trial.
DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains.
Hernández-Sánchez M, Rodríguez-Vicente AE, González-Gascón Y Marín I, Quijada-Álamo M, Hernández-Sánchez JM, Martín-Izquierdo M, Hernández-Rivas JÁ, Benito R, Hernández-Rivas JM. Hernández-Sánchez M, et al. Exp Hematol. 2019 Apr;72:9-13. doi: 10.1016/j.exphem.2019.02.003. Epub 2019 Feb 23. Exp Hematol. 2019. PMID: 30807786 Free article.
Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications.
Pérez-Carretero C, Hernández-Sánchez M, González T, Quijada-Álamo M, Martín-Izquierdo M, Hernández-Sánchez JM, Vidal MJ, de Coca AG, Aguilar C, Vargas-Pabón M, Alonso S, Sierra M, Rubio-Martínez A, Dávila J, Díaz-Valdés JR, Queizán JA, Hernández-Rivas JÁ, Benito R, Rodríguez-Vicente AE, Hernández-Rivas JM. Pérez-Carretero C, et al. Int J Cancer. 2020 Nov 15;147(10):2780-2792. doi: 10.1002/ijc.33235. Epub 2020 Sep 4. Int J Cancer. 2020. PMID: 32720348
Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia.
Quijada-Álamo M, Pérez-Carretero C, Hernández-Sánchez M, Rodríguez-Vicente AE, Herrero AB, Hernández-Sánchez JM, Martín-Izquierdo M, Santos-Mínguez S, Del Rey M, González T, Rubio-Martínez A, García de Coca A, Dávila-Valls J, Hernández-Rivas JÁ, Parker H, Strefford JC, Benito R, Ordóñez JL, Hernández-Rivas JM. Quijada-Álamo M, et al. Clin Transl Med. 2021 Feb;11(2):e304. doi: 10.1002/ctm2.304. Clin Transl Med. 2021. PMID: 33634999 Free PMC article.
115 results